test

KPWHRI in the Media

 

News media often cover Kaiser Permanente Washington research.
Here are selected mentions.

 

2020


july 131

Phase 3 clinical trial of investigational vaccine for COVID-19 begins

Read NIAID news release.

A large phase 3 efficacy trial of an investigational mRNA vaccine for the COVID-19 virus is starting, and the 89 study sites are anticipated to include KPWHRI, which launched the phase 1 trial of this vaccine:


COVID-19 vaccine well tolerated, generates immune response

Read news release.

An investigational mRNA vaccine designed to protect against COVID-19 was generally well tolerated and prompted neutralizing activity in healthy adults, according to interim results from a phase 1 trial published in the New England Journal of Medicine by lead author Lisa A. Jackson, MD, MPH, and colleagues:


Kaiser Permanente launches first coronavirus vaccine trial

Read story.

A large phase 3 efficacy trial of an mRNA vaccine for the COVID-19 virus will start this month and will include Kaiser Permanente Washington Health Research Group (KPWHRI), which launched the phase 1 trial of this vaccine:


june 130

Seattle team to build hi-res brain map of Alzheimer’s disease

Read news release.

The Allen Institute for Brain Science has teamed up with UW Medicine and KPWHRI’s Adult Changes in Thought (ACT) study to explore how Alzheimer’s disease happens in the brain:


The ACT Study: Looking toward the future

Read blog.

A UW School of Nursing researcher describes analyzing data from the joint KPWHRI-UW ACT study, to better understand the relationship between neighborhoods and cognitive health:


How epidemiologists predict the future of COVID-19

Read story.

Aruna Kamineni, PhD, and Diana Buist, PhD, were among epidemiologists talking about when they’d send their children to school or camp during the pandemic; and Mike Jackson, PhD, cautioned that the less-than-scientific methods of “superforecasters” make it hard to vet their work:


Kaiser Permanente launches first coronavirus vaccine trial

Read story.

A large phase 3 efficacy trial of an mRNA vaccine for the COVID-19 virus will start this month and will include Kaiser Permanente Washington Health Research Group (KPWHRI), which launched the phase 1 trial of this vaccine:


6 Building Blocks helps rural clinics to manage opioids

Read news release.

Led by Michael Parchman, MD, MPH, researchers at Kaiser Permanente and the University of Washington have developed an innovative program to provide primary care clinics with practice support to reduce patients’ use of opioids:


We decreased people’s sedentary time—by an hour a day

Read blog.

Dori Rosenberg, PhD, helped older people to stand and walk more:


may 1–31

Kaiser Permanente launches first coronavirus vaccine trial

Read story.

Lisa A. Jackson, MD, MPH, is leading the first-ever clinical trial of any experimental vaccine targeting the virus that causes COVID-19. Moderna, Inc., produced the vaccine in record time. The National Institute of Allergy and Infectious Diseases is sponsoring the trial, which is taking place at KPWHRI’s Vaccine and Treatment Evaluation Unit. This groundbreaking research is continuing to be widely covered by media outlets around the world, including these:

Coordinating chronic care

Katie Coleman, MSPH, and Brian Austin discuss the multidisciplinary effort needed to optimize care and control costs for people with multiple chronic illnesses:

When does your child need antibiotics?

Read story.

Rita Mangione-Smith, MD, MPH, describes how premature hype surrounding possible therapies for COVID-19 may be hastening another long looming public health threat, overprescribing of the antibiotic azithromycin (with hydroxychloroquine)—possibly resulting in increasing bacterial resistance:

Artificial intelligence: Aiding, not replacing radiologists

Read story.

With University of Washington colleagues and Kaiser Permanente Washington data, KPWHRI researchers are helping to find how artificial intelligence (AI) can be used to increase the accuracy of single-radiologist assessments of mammograms:

How do you know when you’re depressed?

Read story.

Greg Simon, MD, MPH, explores the kind of depression that can follow an event that leaves a person feeling chronically stressed, upset, or bereaved—and how to treat it:

The science of aging brains: ACT collaborations grow

Read story.

Eric B. Larson, MD, MPH, says an update to the Lancet Commission on Dementia Prevention, Intervention, and Care will include pollution as one of the modifiable life-course risk factors:


APRIL 1–30

Coronavirus vaccine trial now includes older people

Read story.

Led by Lisa A. Jackson, MD, MPH, the first-ever trial of any experimental vaccine candidate for COVID-19 virus has expanded to include older adults:


Kaiser Permanente launches first coronavirus vaccine trial

Read story.

Lisa A. Jackson, MD, MPH, is leading the first-ever clinical trial of any experimental vaccine targeting the virus that causes COVID-19. Moderna, Inc., produced the vaccine in record time. The National Institute of Allergy and Infectious Diseases is sponsoring the trial, which is taking place at KPWHRI’s Vaccine and Treatment Evaluation Unit. This groundbreaking research is continuing to be widely covered by media outlets around the world, including these:


When does your child need antibiotics?

Read story.

Rita Mangione-Smith, MD, MPH, advises parents on how to avoid the overuse of antibiotics in children:


Alzheimer’s and dementia: Things are looking up

Read story.

Eric B. Larson, MD, MPH, says alternative and complementary practices may reduce many of the symptoms of people with dementia, including anxiety and depression:


How to maximize screening for colon cancer?

Read story.

Beverly Green, MD, MPH, is featured for her research on increasing colorectal cancer screening rates through mailing home-testing FIT kits to patients:


MARCH 1–31

Kaiser Permanente launches first coronavirus vaccine trial

Read story.

Lisa A. Jackson, MD, MPH, is leading the first-ever clinical trial for a vaccine targeting the virus that causes COVID-19. Moderna, Inc., produced the vaccine in record time. The National Institute of Allergy and Infectious Diseases is sponsoring the trial, which is taking place at KPWHRI’s Vaccine and Treatment Evaluation Unit. This groundbreaking research is being widely covered by media outlets around the world, including these:

National, Mar 16, 2020:

Local, Mar 16, 2020:

International, Mar 16, 2020:


Addictions

Joseph E. Glass, PhD, MSW, and Katharine Bradley, MD, MPH, are among 3 coauthors of a blog on contingency management, a behavioral treatment based on operant conditioning principles. Most often, it means providing something of monetary value to patients to incent them to not use drugs:


Best weight-loss surgery for diabetes and severe obesity?

Watch KPWHRI video.

In this new PCORI video, David Arterburn, MD, MPH, shares the main findings of the PCORnet® Bariatric Study, which compared risks and benefits of the most common types of bariatric surgery to help patients with obesity make informed choices with their physicians:


february 1–29

Vaccine against new coronavirus

Read the NIH trial description and the KPWHRI enrollment web page.

The first clinical trial for a vaccine targeting SARS-CoV-2, which causes COVID-19, will be sponsored by the National Institute of Allergy and Infectious Diseases. The trial will take place at KPWHRI’s Vaccine and Treatment Evaluation Unit, led by Lisa A. Jackson, MD, MPH:


More operations follow gastric bypass than gastric sleeve

Read news release.

David Arterburn, MD, MPH, was interviewed about the rise in second operations after weight-loss surgery:


How effective is acupuncture for chronic back pain?

Read story.

Karen Sherman, PhD, was interviewed about Medicare soon offering coverage for acupuncture treatments for lower back pain:


6 Building Blocks helps rural clinics to manage opioids

Read story.

The AHRQ posted a step-by-step guide to support clinics as they implement effective, guideline-driven care for their patients with chronic pain who are using opioid therapy. Michael Parchman, MD, MPH, led the team that developed Six Building Blocks: A team-based approach to improving opioid management in primary care:


January 1–31

Your brain is a reservoir: Replenish it with these 10 healthy habits

Read story.

Commenting on a study linking sleep problems to cognitive decline and dementia, Eric B. Larson, MD, MPH, cautioned against overreacting with anxiety, because just because a person struggles with sleep, it doesn’t mean they’re destined to have cognitive problems:


5 ways to prevent or delay dementia

Read story.

“Super-agers”—people who age in an unusually healthy way—tend to proactively build a lot of positive, healthy, social activity into their daily lives, according to Eric B. Larson, MD, MPH:


Accountable Communities of Health have made strides

Read story.

KPWHRI’s Center for Community Health and Evaluation found that Washington state’s Accountable Communities of Health (ACH) have evolved into robust, regional organizations that are integral to advancing the state’s health system transformation efforts:


Integrative non-drug therapies treat back pain at reasonable cost

Read story.

Dan Cherkin, PhD, is interviewed about the issues surrounding back pain, including its causes, treatments and costs:


Some links may require a subscription to view the content. Please check the terms and conditions on these websites and follow their rules to avoid violating copyright law when visiting them. We can’t provide you with copies of articles.

For the media

Michael-VonKorff-media_2col.jpg

Are you a member of the news media?

Our goal is to make your job easier. We can quickly arrange for you to interview our scientists about their research or the work of others. We can also provide news releases, photographs, videos, and backgrounders—and access to patients who participate in our research and would like to be interviewed. 


Media contact

For more on Kaiser Permanente Washington Health Research Institute news, please contact:

Rebecca Hughes
Rebecca.F.Hughes@kp.org

206-287-2055
After-hours media line: 206-448-4056

page-twitter-icon.png @KPWaResearch

About Kaiser Permanente Washington Health Research Institute

Kaiser Permanente Washington Health Research Institute (KPWHRI) improves the health and health care of Kaiser Permanente members and the public. The Institute has conducted nonproprietary public-interest research on preventing, diagnosing, and treating major health problems since 1983. Government and private research grants provide our main funding. Follow KPWHRI research on Twitter, Facebook, LinkedIn, or YouTube. For more information, go to: www.kpwashingtonresearch.org.

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.2 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.